Marshall Wace LLP Increases Holdings in DexCom, Inc. (NASDAQ:DXCM)

Marshall Wace LLP lifted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 104.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 539,295 shares of the medical device company's stock after purchasing an additional 275,295 shares during the period. Marshall Wace LLP owned 0.14% of DexCom worth $41,941,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Versant Capital Management Inc bought a new stake in DexCom in the fourth quarter valued at approximately $25,000. Private Trust Co. NA lifted its holdings in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after acquiring an additional 167 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new stake in DexCom during the 4th quarter worth approximately $38,000. Institutional investors own 97.75% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on DXCM shares. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Citigroup lifted their target price on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Mizuho assumed coverage on shares of DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. Finally, Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $99.00.

DexCom Trading Up 1.3 %

NASDAQ DXCM traded up $0.86 during mid-day trading on Wednesday, reaching $67.19. 1,616,610 shares of the stock were exchanged, compared to its average volume of 4,219,631. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The stock has a market cap of $26.35 billion, a P/E ratio of 46.99, a P/E/G ratio of 2.30 and a beta of 1.50. The stock has a 50 day simple moving average of $74.27 and a 200-day simple moving average of $76.66. DexCom, Inc. has a one year low of $57.52 and a one year high of $139.24.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 105,009 shares of company stock worth $8,044,178. 0.32% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.